Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06569368 · ClinicalTrials.gov registry record · Phase 2
Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
A Phase 2 study of Rectal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06569368: Recruiting Phase 2 study of Rectal Adenocarcinoma, sponsored by M.D. Anderson Cancer Center.
NCT06569368 is a Phase 2 study of Rectal Adenocarcinoma that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 60 participants, below the 121-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06569368, a Phase 2 study of Rectal Adenocarcinoma, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if adding metronidazole to standard therapy can decrease populations of Fusobacterium nucleatum (F. nucleatum) and other anaerobes (small organisms that cause infections) in participants with rectal cancer receiving neoadjuvant therapy, compared to neoadjuvant therapy alone.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Metronidazole
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-07-10 |
| Est. Completion | 2028-10-31 |
| Phase | Phase 2 |
What NCT06569368 shows while recruiting
NCT06569368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 121-participant average among 17 other Rectal Adenocarcinoma trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Rectal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Metronidazole is the first listed.
NCT06569368 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06569368 about?
NCT06569368 is a clinical study titled "Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy". To learn if adding metronidazole to standard therapy can decrease populations of Fusobacterium nucleatum (F. nucleatum) and other anaerobes (small organisms that cause infections) in participants with rectal cancer receiving neoadjuvant therapy, compared to neoadjuvant therapy alone.
What is the current status of trial NCT06569368?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2024-07-10. Estimated completion is 2028-10-31.
What conditions does trial NCT06569368 study?
This clinical trial studies the following conditions: Rectal Adenocarcinoma.
What interventions are being tested in trial NCT06569368?
The interventions under investigation include: Metronidazole (DRUG).
Who is sponsoring clinical trial NCT06569368?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06569368 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rectal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06569368's enrollment target sits among peer trials
60 5th of 17 higher than 13 of 17 other Rectal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rectal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
RECRUITING · Phase 2
-
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
RECRUITING · Phase 2
-
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
RECRUITING · Phase 2
-
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
ExIST Study of LY2157299 (Galunisertib) in Rectal Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy